John Bradley Holcomb

CIK: 0002092279

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)5 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

INKT

MiNK Therapeutics, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (5 total)

INKT
MiNK Therapeutics, Inc.
Sep 1, 2026
Award(A)
Direct
1.2K shares at avg. $10.95$14K
INKT
MiNK Therapeutics, Inc.
Jun 1, 2026
Award(A)
Direct
1.1K shares at avg. $12.38$14K
INKT
MiNK Therapeutics, Inc.
Mar 2, 2026
Award(A)
Direct
1.2K shares at avg. $10.90$14K
INKT
MiNK Therapeutics, Inc.
Dec 1, 2025
Award(A)
Direct
1.1K shares at avg. $11.09$13K
INKT
MiNK Therapeutics, Inc.
Sep 23, 2025
Award(A)
Stock Option (Right to Buy)
Direct
4.2K shares-

		Type	Shares	Price		Ownership
Sep 1, 2026	INKT MiNK Therapeutics, Inc.	Award(A)	1,233	$10.95	$13,501	Direct
Jun 1, 2026	INKT MiNK Therapeutics, Inc.	Award(A)	1,091	$12.38	$13,507	Direct
Mar 2, 2026	INKT MiNK Therapeutics, Inc.	Award(A)	1,239	$10.90	$13,505	Direct
Dec 1, 2025	INKT MiNK Therapeutics, Inc.	Award(A)	1,128	$11.09	$12,510	Direct
Sep 23, 2025	INKT MiNK Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	4,174	-	-	Direct

1-5 of 5 transactions

About Holcomb John Bradley

Holcomb John Bradley (SEC CIK 0002092279) files insider reports with the SEC as Director of MiNK Therapeutics, Inc. (INKT).

Signal8 holds 4 ownership filings by Holcomb John Bradley, all Form 4s, filed between Dec 3, 2025 and Sep 2, 2026. Those filings report 5 transactions, from Sep 23, 2025 to Sep 1, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Holcomb John Bradley's filings is in NEW YORK, NY.

Recent filings by Holcomb John Bradley

Sep 1, 2026: Grant or award of INKT shares (Form 4, code A).
Jun 1, 2026: Grant or award of INKT shares (Form 4, code A).
Mar 2, 2026: Grant or award of INKT shares (Form 4, code A).
Dec 1, 2025: Grant or award of INKT shares (Form 4, code A).
Sep 23, 2025: Grant or award of INKT derivative securities (Form 4, code A).

Other insiders filing for MiNK Therapeutics, Inc. (INKT)

Buell Jennifer, Chief Executive Officer
WIINBERG ULF, Director
Behner Peter, Director
Ryan Barbara, Director
Corvese Brian, Director
Orilall Melissa, Principal Financial Officer

How to read Form 4 transaction codes